Upadacitinib Versus Filgotinib in Ulcerative Colitis: Is the Evidence Sufficient to Inform Treatment Decisions?
2024

Comparing Upadacitinib and Filgotinib for Ulcerative Colitis

Sample size: 168 Editorial Evidence: moderate

Author Information

Author(s): Vuyyuru Sudheer Kumar, Yuan Yuhong, Jairath Vipul

Primary Institution: Western University London Canada

Hypothesis

Is the evidence sufficient to inform treatment decisions between upadacitinib and filgotinib?

Conclusion

Upadacitinib may have superior efficacy compared to filgotinib, especially in patients with prior biologic exposure, despite higher rates of adverse events.

Supporting Evidence

  • Upadacitinib was associated with significantly higher risk of clinical response and clinical remission compared to filgotinib.
  • Real-world studies have shown similar efficacy between upadacitinib and tofacitinib.
  • Adverse events were more common with upadacitinib, including skin rash and acne.

Takeaway

This study looks at two medicines for treating a gut disease and finds that one might work better than the other, but it also causes more side effects.

Methodology

A retrospective, real-world observational study with multivariable analysis and propensity score matching.

Potential Biases

Selection bias and residual confounding may affect the results due to the nature of the study design.

Limitations

The study's retrospective design and relatively small sample size may limit the findings.

Participant Demographics

Patients treated at three tertiary care centers in Japan, median follow-up of approximately 6 months.

Statistical Information

Confidence Interval

95% CI [1.09–1.80] for clinical response; 95% CI [1.16–2.05] for clinical remission.

Digital Object Identifier (DOI)

10.1002/ueg2.12709

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication